Abstract
Opioid receptors (ORs) in the myenteric plexus mediate the antimotility actions of opioids in the small intestine. In this study, ORs modulating neurogenic circular muscle contractions in the porcine ileum were characterized by pharmacological and immunohistochemical approaches. Circular muscle-myenteric plexus strips manifested tetrodotoxin- and atropine-sensitive contractions during (ON) and after (OFF) electrical field stimulation. The κ-OR agonists U-50,488H and U-69,593 inhibited ON contractions (pIC50 = 7.61 and 8.22, respectively). U-69,593 action was inhibited by the κ-OR antagonist norbinaltorphimine with an antagonist equilibrium constant (Ke) of 4.2 nM. Selective δ-OR agonists [d-Ala2]-deltorphin II, DSLET, DADLE, SNC80, and DPDPE inhibited OFF contractions (pIC50 = 9.17, 8.63, 8.50, 8.26, and 7.47, respectively). The selective δ-OR antagonist naltriben reduced the inhibitory actions of SNC80 and DSLET with respective Ke values of 2.3 and 3.0 nM. In addition, norbinaltorphimine inhibited the actions of these agonists with respective Ke values of 0.7 and 4.2 nM. The μ-OR agonists DAMGO, loperamide, or morphine exhibited relatively low activities in inhibiting ON and OFF contractions. Using primary antisera directed toward cloned opioid receptors, δ-OR immunoreactivity was observed to be localized alone or in combination with κ-OR immunoreactivity in myenteric neurons; μ-OR immunoreactivity was absent. The results suggest that myenteric δ- and κ-opioid receptors mediate the antitransit effects of opioids in the porcine small intestine. These receptors may be functionally coupled in a subpopulation of myenteric neurons.
Footnotes
-
Send reprint requests to: David R. Brown, Ph.D., Department of Veterinary PathoBiology, University of Minnesota, 1988 Fitch Ave., St. Paul, MN 55108-6010. E-mail:brown013{at}tc.umn.edu
-
This investigation was supported by National Institutes of Health Grants R01 DA-10200 to D.R.B. and R01 DA-01533 to P.S.P. S.P. was supported by a Royal Thai Government scholarship.
- Abbreviations:
- OR
- opioid receptor
- LMMP
- longitudinal muscle-myenteric plexus
- DAMGO
- [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
- DPDPE
- [d-Pen2,d-Pen5]-enkephalin
- DADLE
- [d-Ala2,d-Leu5]-enkephalin
- DSLET
- [d-Ser2,Leu5]-enkephalin-Thr
- SNC80
- (+)-4-[(αR)-α(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl)-N,N-diethylbenzamide
- U-50,488H
- trans-(±)-3,4-dichloro-N-methyl-N-(2-[1-pyrrolidinyl]cyclohexyl) benzene-acetamide methanesulfonate
- U-69,593
- (5α,7α,8β)-(+)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)]-benzeneacetamide
- norBNI
- norbinaltorphimine
- NTB
- naltriben
- BNTX
- 7-benzylidenenaltrexone
- mN
- millinewton
- EFS
- electrical field stimulation
- PBS
- phosphate-buffered saline
- TM
- transmembrane
- Received September 28, 2000.
- Accepted December 21, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|